Stock Events

Stock Events

iBio 

$1.4200
172
-$0.03-2.07% Thursday 03:06

Statistics

Day High
1.42
Day Low
1.41
52W High
1.94
52W Low
1.4
Volume
202
Avg. Volume
-
Mkt Cap
91.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.21
-0.15
-0.1
-0.05
Expected EPS
-0.072
Actual EPS
N/A

Financials

-4,594.25%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
400,000Revenue
-18.38MNet Income

Analyst Ratings

5.00Average Price Target
The highest estimate is 5.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IBIO.BOATS. It's not an investment recommendation.
Tesla
35
TSLA
Apple
31
AAPL
Microsoft
25
MSFT
Amazon
25
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.69B
Novavax is a competitor because it also focuses on developing vaccines using innovative technology, similar to iBio's plant-based expression system.
Moderna
MRNA
Mkt Cap58.11B
Moderna competes in the same space by developing mRNA vaccines, offering an alternative to iBio's technology for rapid vaccine development.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a major player in vaccine development and distribution, directly competing with iBio's efforts in the vaccine market.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech, in partnership with Pfizer, competes in the mRNA vaccine space, offering alternatives to iBio's vaccine technologies.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson develops and markets vaccines, including its COVID-19 vaccine, competing with iBio's vaccine development efforts.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in vaccine development, including its COVID-19 vaccine, making it a competitor to iBio.
Sanofi
SNY
Mkt Cap106.01B
Sanofi is a large pharmaceutical company that competes with iBio in the vaccine market, including efforts in developing COVID-19 vaccines.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline is a competitor due to its extensive vaccine portfolio, which competes with iBio's vaccine development projects.
Dyadic International DE
DYAI
Mkt Cap20.84M
Dyadic International competes with iBio by using its proprietary C1-cell protein production platform for developing and manufacturing biopharmaceuticals, including vaccines.
Incyte
INCY
Mkt Cap25.69B
Incyte competes with iBio in the broader biopharmaceutical space, focusing on the discovery, development, and commercialization of proprietary therapeutics.

About

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Show more...
CEO
ISIN
US4510337086

Listings

STU
DE
0JV0.STU
F
DE
0JV0.F
MU
DE
0JVN.MU
MU
DE
0JV0.MU

0 Comments

Share your thoughts

FAQ

What is iBio stock price today?▼
The current price of IBIO.BOATS is $1.42 USD — it has decreased by -2.07% in the past 24 hours. Watch iBio stock price performance more closely on the chart.
What is iBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange iBio stocks are traded under the ticker IBIO.BOATS.
What is iBio market cap?▼
Today iBio has the market capitalization of 91.32M
When is the next iBio earnings date?▼
iBio is going to release the next earnings report on November 17, 2026.
What were iBio earnings last quarter?▼
IBIO.BOATS earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.07 USD resulting in a +27.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is iBio revenue for the last year?▼
iBio revenue for the last year amounts to 400,000 USD.
What is iBio net income for the last year?▼
IBIO.BOATS net income for the last year is -18.38M USD.
In which sector is iBio located?▼
iBio operates in the Other sector.
When did iBio complete a stock split?▼
The last stock split for iBio was on November 29, 2023 with a ratio of 1:20.